{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:42:01Z","timestamp":1788090121376,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe a potential emerging neuropsychiatric adverse effect, abnormal dreams or night terrors, associated with atogepant (a calcitonin gene\u2013related peptide receptor antagonist) observed in 4 patients treated at a tertiary headache clinic, and to place these observations in the context of existing postmarketing pharmacovigilance signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Four patients with migraine developed vivid abnormal dreams, nightmares, or night terrors after starting atogepant for migraine prevention. Symptoms were bothersome, often led to atogepant discontinuation, and generally resolved after stopping use of the drug; one patient improved despite continuing therapy. Although confounders existed, timing and causality assessment supported a possible association, consistent with US Food and Drug Administration Adverse Event Reporting System pharmacovigilance signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Abnormal dreams and night terrors may represent an underrecognized adverse effect of atogepant. Based on this case series, the effect appears potentially reversible with discontinuation and may diminish over time in some patients who continue therapy. For patients who are taking atogepant and report sleep disturbances and dream-related symptoms, a possible correlation with atogepant should be considered. During follow-up, proactively asking about sleep disturbances and dream-related symptoms should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag213","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:55:15Z","timestamp":1783770915000},"source":"Crossref","is-referenced-by-count":1,"title":["Abnormal dreams and night terrors with atogepant: A case series"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4927-1795","authenticated-orcid":false,"given":"Jason","family":"To","sequence":"first","affiliation":[{"name":"University of Vermont Medical Center , Burlington, VT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7521-1068","authenticated-orcid":false,"given":"Heather","family":"Cournoyer","sequence":"additional","affiliation":[{"name":"University of Vermont Medical Center , Burlington, VT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-4961","authenticated-orcid":false,"given":"Amanda G","family":"Kennedy","sequence":"additional","affiliation":[{"name":"University of Vermont Larner College of Medicine , Burlington, VT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-707X","authenticated-orcid":false,"given":"Adam S","family":"Sprouse-Blum","sequence":"additional","affiliation":[{"name":"University of Vermont , Burlington, VT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4087-2853","authenticated-orcid":false,"given":"Julie","family":"MacDougall","sequence":"additional","affiliation":[{"name":"University of Vermont Medical Center , Burlington, VT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"1","key":"2026072114463817800_zxag213-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"10","key":"2026072114463817800_zxag213-B2","doi-asserted-by":"publisher","first-page":"102348","DOI":"10.1016\/j.xcrm.2025.102348","article-title":"GBD 2021 Headache Collaborators. Global, regional, and national burden of headache disorders, 1990-2021, with forecasts to 2050: a Global Burden of Disease study 2021","volume":"6","author":"Wijeratne","year":"2025","journal-title":"Cell Rep Med"},{"issue":"2","key":"2026072114463817800_zxag213-B3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","volume":"103","author":"Russo","year":"2023","journal-title":"Physiol Rev"},{"issue":"4","key":"2026072114463817800_zxag213-B4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"issue":"1","key":"2026072114463817800_zxag213-B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","article-title":"Atogepant: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"2026072114463817800_zxag213-B6","doi-asserted-by":"publisher","first-page":"e209584","DOI":"10.1212\/WNL.0000000000209584","article-title":"Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial","volume":"103","author":"Goadsby","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"2026072114463817800_zxag213-B7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12883-025-04260-y","article-title":"Variant angina associated with a CGRP receptor antagonist: a case report","volume":"25","author":"Jeon","year":"2025","journal-title":"BMC Neurol"},{"issue":"10","key":"2026072114463817800_zxag213-B8","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.xkme.2025.101092","article-title":"Acute interstitial nephritis induced by monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) \u2014 unveiling a new association: a case report","volume":"7","author":"Vargas-Brochero","year":"2025","journal-title":"Kidney Med"},{"issue":"1","key":"2026072114463817800_zxag213-B9","doi-asserted-by":"publisher","first-page":"3331024241297673","DOI":"10.1177\/03331024241297673","article-title":"Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: a systematic review and potential clinical implications","volume":"45","author":"van der Arend","year":"2025","journal-title":"Cephalalgia"},{"issue":"2","key":"2026072114463817800_zxag213-B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2026072114463817800_zxag213-B11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s10194-020-01192-5","article-title":"Migraine and sleep disorders: a systematic review","volume":"21","author":"Tiseo","year":"2020","journal-title":"J Headache Pain"},{"issue":"10","key":"2026072114463817800_zxag213-B12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1111\/j.1526-4610.2008.01175.x","article-title":"Are sleep difficulties associated with migraine attributable to anxiety and depression?","volume":"48","author":"Vgontzas","year":"2008","journal-title":"Headache"},{"issue":"6","key":"2026072114463817800_zxag213-B13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/14740338.2024.2377347","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for atogepant","volume":"24","author":"Wen","year":"2025","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"2026072114463817800_zxag213-B14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2024.2393268","article-title":"Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis","volume":"24","author":"Zhang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026072114463817800_zxag213-B15","doi-asserted-by":"publisher","first-page":"1431562","DOI":"10.3389\/fphar.2024.1431562","article-title":"Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s Adverse Event Reporting System databases","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026072114463817800_zxag213-B16","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","article-title":"Adverse event reporting of four anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA Adverse Event Reporting System","volume":"14","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026072114463817800_zxag213-B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14740338.2023.2250720","article-title":"Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database","volume":"23","author":"Wang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2026072114463817800_zxag213-B18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/head.14871","article-title":"Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: results from the TANDEM study","volume":"65","author":"Ailani","year":"2025","journal-title":"Headache"},{"key":"2026072114463817800_zxag213-B19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02091-3","article-title":"Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System","author":"Song","journal-title":"J Headache Pain"},{"issue":"35","key":"2026072114463817800_zxag213-B20","doi-asserted-by":"publisher","first-page":"e00325","DOI":"10.1002\/advs.202500325","article-title":"Calcitonin gene-related peptide (CGRP)-expressing neurons in the external lateral parabrachial area regulate pain-induced sleep disturbances","volume":"12","author":"Lynch","year":"2025","journal-title":"Adv Sci (Weinh)"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag213\/68764233\/zxag213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag213\/68764233\/zxag213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:46:41Z","timestamp":1784659601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag213\/8733253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag213","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"zxag213"}}